Reimbursed Care Access in Cameroon

Currently classified as a strictly controlled substance under national drug‑control legislation (Law No. 97‑019 and implementing provisions), with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug‑control legislation (Law No. 97‑019 and related penal code provisions), with no authorized medical use or reimbursement outside of approved clinical research. #

Esketamine (nasal S‑ketamine, e.g., Spravato) is not known to have a national marketing authorization or publicly funded reimbursement pathway in Cameroon; there is no evidence of a Cameroonian regulatory approval or public coverage scheme for esketamine in available national legislation or formal health‑system sources. Ketamine (racemate) is used clinically as an essential anesthetic in Cameroon (and is listed on international essential‑medicines/medical supply catalogues used in low‑resource settings), but esketamine as an approved/ reimbursed antidepressant product has not been documented in Cameroonian regulatory or public‑payor sources. For the country’s general legal framework that governs controlled psychotropic drugs and the requirement for authorization for medical use, see Law No. 97‑019. # #

Ketamine is an established, routinely used anesthetic and analgesic agent in Cameroon clinical settings (including human and veterinary medicine) and is included in international essential‑medicine and humanitarian supply catalogues used in low‑resource settings; its medical use is permitted under the national law framework that allows authorized controlled medicines for clinical practice. # #

Regulatory/coverage context and reimbursement: Cameroon’s public health financing is limited and there is no publicly documented, nationwide reimbursement programme specifically for ketamine when used for psychiatric indications; ketamine is principally procured and used as an essential anesthetic in hospitals and surgical facilities. In practice, ketamine is typically available within facility formularies (public and private hospitals, NGOs, humanitarian organisations) where procurement and use follow national controlled‑medicines rules and hospital procurement channels rather than a centralized, reimbursed outpatient mental‑health therapy programme. Procurement and clinical use will therefore be institutionally arranged and funded (hospital budgets, out‑of‑pocket patient payments, or NGO support) rather than through a formal national pharmaceutical reimbursement schedule. # #

Clinical‑vs‑legal nuance: international bodies (WHO/WMA) have emphasised retaining medical access to ketamine in low‑resource settings, and Cameroon’s legal regime distinguishes authorized medical use (permitting supply/possession for clinical practice under license) from illicit possession/trafficking; illicit trafficking and non‑medical possession carry heavy criminal penalties under Law No. 97‑019. #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. The national drug‑control law (Law No. 97‑019) criminalizes production, possession and distribution of substances listed in the implementing tables and provides heavy penalties for trafficking. #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. Possession, importation or distribution outside licensed research/medical channels would be prosecuted under Cameroon’s narcotics law. #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. Note: iboga (Tabernanthe iboga) has cultural presence in parts of Central Africa (notably Gabon) and illegal wild‑harvesting and cross‑border trade from neighbouring countries has been reported, but that does not imply legal medical availability or reimbursement in Cameroon; trafficking and unauthorized export/import are subject to the penalties in Law No. 97‑019. # #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. Preparations containing DMT intended for human consumption would fall under the controlled substances regime and are not authorized for clinical practice or reimbursement. #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. Mescaline and extracts intended for psychoactive use would be treated as illicit under Cameroon’s narcotics law. (Note: growing of certain cacti in itself may not always be explicitly regulated in all jurisdictions, but extraction and possession of mescaline are controlled under the national law framework.) #

Currently classified as a strictly controlled substance under national drug‑control legislation, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines of the 2C family are covered by broad psychotropic control provisions and subject to criminal penalties for unauthorized manufacture, possession or distribution under Law No. 97‑019. #